NASDAQ:RADX - Nasdaq - ADR - Currency: USD
We assign a fundamental rating of 3 out of 10 to RADX. RADX was compared to 551 industry peers in the Biotechnology industry. The financial health of RADX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, RADX is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.34% | ||
ROE | -78.79% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -1.8 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.37 | ||
Quick Ratio | 3.37 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
4.675
-0.17 (-3.61%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 33.14 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.05 | ||
P/tB | 10.72 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.34% | ||
ROE | -78.79% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.37 | ||
Quick Ratio | 3.37 | ||
Altman-Z | -1.8 |